{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:55:33Z","timestamp":1793778933189,"version":"4.6.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.vaccine.2012.09.041","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T08:43:37Z","timestamp":1366188217000},"page":"B194-B196","source":"Crossref","is-referenced-by-count":90,"special_numbering":"S2","title":["The need and challenges for development of an Epstein-Barr virus vaccine"],"prefix":"10.1016","volume":"31","author":[{"given":"Jeffrey I.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward S.","family":"Mocarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Raab-Traub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Corey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Nabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2012.09.041_bib0005","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0010","doi-asserted-by":"crossref","unstructured":"Balfour HH, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. Behavior, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis, in press.","DOI":"10.1093\/infdis\/jis646"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1440-1827.2010.02533.x","article-title":"Epstein-Barr virus and gastric carcinoma","volume":"60","author":"Fukayama","year":"2010","journal-title":"Pathol Int"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0020","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/ijc.21731","article-title":"The global burden of infection-associated cancers in the year 2002","volume":"118","author":"Parkin","year":"2006","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0025","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa023141","article-title":"Characteristics of Hodgkin's lymphoma after infectious mononucleosis","volume":"349","author":"Hjalgrim","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0030","series-title":"Viral infections of humans: epidemiology and control","first-page":"935","article-title":"Nasopharyngeal carcinoma","author":"de-The","year":"1997"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0035","series-title":"Viral infections of humans: epidemiology and control","first-page":"895","article-title":"Epstein-Barr virus and malignant lymphomas","author":"Evans","year":"1997"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/318287a0","article-title":"Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine","volume":"318","author":"Epstein","year":"1985","journal-title":"Nature"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.09.041_bib0045","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/jmv.1890270210","article-title":"Vero cell-expressed Epstein-Barr virus (EBV) gp350\/220 protects marmosets from EBV challenge","volume":"27","author":"Emini","year":"1989","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0050","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1128\/JVI.76.1.421-426.2002","article-title":"Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model","volume":"76","author":"Rivailler","year":"2002","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0055","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1126\/science.276.5321.2030","article-title":"An animal model for acute and persistent Epstein-Barr virus infection","volume":"276","author":"Moghaddam","year":"1997","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.vaccine.2012.09.041_bib0060","doi-asserted-by":"crossref","first-page":"e1002308","DOI":"10.1371\/journal.ppat.1002308","article-title":"Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge","volume":"7","author":"Sashihara","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0065","first-page":"171","article-title":"First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen","volume":"84","author":"Gu","year":"1995","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0070","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0075","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/JVI.01409-07","article-title":"Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis","volume":"82","author":"Elliott","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0080","series-title":"Vaccines for the 21st century: a tool for decision making","author":"Stratton","year":"2000"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0085","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","article-title":"Cellular responses to viral infection in humans: lessons from Epstein-Barr virus","volume":"25","author":"Hislop","year":"2007","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0090","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa011610","article-title":"Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men","volume":"345","author":"Chien","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0095","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.bjc.6603609","article-title":"Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma","volume":"96","author":"Ji","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2012.09.041_bib0100","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"issue":"107","key":"10.1016\/j.vaccine.2012.09.041_bib0105","doi-asserted-by":"crossref","first-page":"107fs7","DOI":"10.1126\/scitranslmed.3002878","article-title":"Epstein-Barr virus: an important vaccine target for cancer prevention","volume":"3","author":"Cohen","year":"2011","journal-title":"Sci Transl Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12013618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T18:26:56Z","timestamp":1539714416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12013618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":21,"alternative-id":["S0264410X12013618"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.09.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}